{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP04684",
    "Peptide Name": "Mastoparan-R1 ( Mastoparan-L analog, synthetic AMPs, Lys-rich, UCLL1)",
    "Source": "Joker generated, amino acid substitution, animal-derived, natural derivative",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "KILKRLAAKIKKIL",
    "Sequence Length": 14,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Helix",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 6,
    "Boman Index": 0.68,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "57%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that this sequence is similar (66.67%) toMastoparan-LK: 36%, I=L: 21%, A: 14%.Activity: Active against A-baumannii clinical isolate 003326263 (MIC >32 uM), E-cloacae clinical isolate 1383251 (MIC > 32 uM), E. coli ATCC 25922 or KpC+ 001812446 or BL21 (MIC 2-8 uM), K. pneumoniae ATCC 13883  (MIC 8 uM),  K-pneumoniae KpC+ 001825971 (MIC >32 uM),   S-aureus ATCC 25923 or MRSA (MIC >32 uM),  S. aureus ATCC 12600 (MIC 4 uM),   P. aeruginosa PA14 or PAO1 (MIC 4 uM).In vitro toxicity: human RBC: 3% lysis at 100 uM (HC50 > 100 uM), poorly hemo.lytic. 3T3-L1 (IC50 > 100 uM), HUVEC (IC50 > 100 uM), human prostate cancer PC-3 (IC50 > 100 uM), human breast cancer, MCF-7 (IC50 > 100 uM), and human colon adenocarcinoma HT-29 (IC50 > 100 uM).Structure:  random coil in water or POPC and helical in 30% TFE, 25 mM SDS, POPC/POPG (most helical), indicating negatively charged lipid is required for helix formation.",
    "Author": "Oshiro KGN, CÃ¢ndido ES, Chan LY, Torres MDT, Monges BED, Rodrigues SG, Porto WF, Ribeiro SM, Henriques ST, Lu TK, de la Fuente-Nunez C, Craik DJ, Franco OL, Cardoso MH.2019",
    "Reference": "J Med Chem. 2019 Sep 12;62(17):8140-8151. doi: 10.1021/acs.jmedchem.9b00915.PubMed",
    "Title": "Computer-Aided Design of Mastoparan-like Peptides Enables the Generation of Nontoxic Variants with Extended Antibacterial Properties."
  },
  "3D Structure": []
}